グラヌロサイトコロニー刺激因子とグラヌロサイトマクロファージコロニー刺激因子は,アポリポプロテインE欠乏マウスの動脈硬化症を悪化させる
Amir Haghighat1, Daiana Weiss, Matthew K Whalin
1Cardiology Division, Emory University School of Medicine, 1639 Pierce Dr, Atlanta, GA 30322, USA.
Circulation
|April 4, 2007
まとめ
顆粒細胞コロニー刺激因子 (G-CSF) と顆粒細胞マクロファージコロニー刺激因子 (GM-CSF) は,動脈硬化症のマウスモデルにおける血管修復を改善しませんでした. 代わりに,これらの成長因子は動脈硬化性病変の範囲を悪化させ,先発的血管性を増加させた.
科学分野:
- 心血管科学の研究について
- 免疫学 免疫学とは
- 再生医学は,再生医療である.
背景:
- 骨髄由来の原始細胞は,血管修復に寄与する可能性があります.
- 血管修復のために,原始細胞を花粉細胞コロニー刺激因子 (G-CSF) と花粉細胞マクロファージコロニー刺激因子 (GM-CSF) で動員することが研究されている.
- 短期間のG-CSFまたはGM-CSFの投与が動脈硬化に与える影響は不明である.
研究 の 目的:
- 動脈硬化症に対するG-CSFとGM-CSFの治療効果を調査する.
- マウスモデルでG-CSFまたはGM-CSFの投与が動脈硬化病変の発生に影響するかどうかを判断する.
主な方法:
- アポリポプロテインE欠乏症のマウスは,8週間G-CSFまたはGM-CSF (10ミクログxkg(-1) xd(-1) s.c.) を投与した.
- マウスは,治療期間中,高脂肪食を摂取し続けました.
- 動脈硬化病変の範囲,炎症性細胞の浸透,遺伝子発現を評価した.
主要な成果:
- G-CSFとGM-CSFの両方の治療は,動脈硬化病変の範囲の増加につながりました.
- 炎症性細胞または炎症性遺伝子発現の有意な増加は観察されなかった.
- アドベント的血管性が大幅に増加し,vasa vasorum.の新血管化を示唆しました.
結論:
- G-CSFとGM-CSFの投与は,この動脈硬化モデルにおいて有益な効果を示さなかった.
- G-CSFとGM-CSFの両方が動脈硬化症の悪化をもたらしました.
- Vasa vasorumの新血管化は,動脈硬化症の悪化に起因する可能性がある.
関連する概念動画
Inflammation
Overview
Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


